RxDoctor Payments Data

Michael McFarland, DO

Internal Medicine · Azle, TXNPI 1881658714

Payments from drug & device makers

$665in general payments, 2019–2025

Across 40 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$153
  • Teva Pharmaceuticals USA, Inc.$127
  • Lilly USA, LLC$71
  • Takeda Pharmaceuticals U.S.A., Inc.$54
  • Vivus LLC$45
  • Antares Pharma, Inc.$40
  • plus $176 from 9 others

What the payments were for

  • Food & beverage$63996%
  • Education$264%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$665 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$25,922
Medicare patients
71
Services billed
255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin19$28,553
EliquisApixaban28$24,682
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$23,688
RybelsusSemaglutide17$21,078
JanuviaSitagliptin Phosphate19$18,701
TrulicityDulaglutide11$18,123
SuboxoneBuprenorphine Hcl/Naloxone Hcl16$14,294
OzempicSemaglutide12$13,212
FarxigaDapagliflozin Propanediol15$12,855
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl83$9,487
Breo ElliptaFluticasone/Vilanterol11$4,316
Liothyronine Sodium103$4,192
Levothyroxine Sodium445$4,094
Np ThyroidThyroid,pork55$2,573
Testosterone Cypionate41$2,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$33$28,55319 claims
GSKTrelegy Ellipta, Breo Ellipta$36$28,00440 claims
MerckJanuvia$11$18,70119 claims
Lilly USA, LLCTrulicity$71$18,12311 claims
Indivior Inc.Suboxone$11$14,29416 claims
IBSA Pharma Inc.Tirosint$17$1,50911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Azle

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →